With respect to dosing regimens and duration of therapy using dupilumab in the pediatric and adolescent age groups, what do the trials, FDA approval guidance, and your clinical experience suggest as practical roadmaps in this population?

Name: With respect to dosing regimens and duration of therapy using dupilumab in the pediatric and adolescent age groups, what do the trials, FDA approval guidance, and your clinical experience suggest as practical roadmaps in this population?
Uploaded: 2020-06-10T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Created by

Presenter

Peter Lio, MD

Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois